Literature DB >> 18505344

Expression of DPC4/Smad4 in non-small-cell lung carcinoma and its relationship with angiogenesis.

Z Ke1, X Zhang, L Ma, L Wang.   

Abstract

The DPC4 influences tumourigenesis and tumor progression by various mechanisms, including angiogenesis. The aim of this study was to determine whether the expression of DPC4 is related to the angiogenesis in lung cancer and whether it could be involved in its clinical behaviour. Immunohistochemistry revealed that DPC4 was expressed at high level in normal broncho-tracheal epithelium, but at low level in tumor tissues, and closely correlated with tumor lymph node metastasis. This result was further confirmed by Western blot analysis. Furthermore, carcinomas with high DPC4 expression demonstrated low VEGF expression and low MVD (microvessel density) labelled with CD34. In addition, DPC4 siRNA in A549 cells also showed that DPC4 could decrease VEGF protein and mRNA expression, and increase TSP1 protein and mRNA expression. Our findings indicated that DPC4 might be an important biomarker for malignant transformation and be involved in preventing the tumor metastasis by inhibiting tumor angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18505344

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  12 in total

1.  The expression and underlying angiogenesis effect of DPC4 and VEGF on the progression of cervical carcinoma.

Authors:  Yanni A; Ying Li; Shuping Zhao
Journal:  Oncol Lett       Date:  2017-12-11       Impact factor: 2.967

2.  Roles of VEGF-C and Smad4 in the lymphangiogenesis, lymphatic metastasis, and prognosis in colon cancer.

Authors:  Xuemei Li; Baoquan Liu; Jianbing Xiao; Ying Yuan; Jing Ma; Yafang Zhang
Journal:  J Gastrointest Surg       Date:  2011-07-23       Impact factor: 3.452

3.  AEG-1 expression characteristics in human non-small cell lung cancer and its relationship with apoptosis.

Authors:  Zun-Fu Ke; Xiaopeng Mao; Cao Zeng; Shanyang He; Shuhua Li; Lian-Tang Wang
Journal:  Med Oncol       Date:  2013-01-10       Impact factor: 3.064

4.  SMAD4 mutation correlates with poor prognosis in non-small cell lung cancer.

Authors:  Yue Wang; Qianqian Xue; Qiang Zheng; Yan Jin; Xuxia Shen; Mu Yang; Xiaoyan Zhou; Yuan Li
Journal:  Lab Invest       Date:  2020-12-10       Impact factor: 5.662

5.  Clinical outcome and expression of mutant P53, P16, and Smad4 in lung adenocarcinoma: a prospective study.

Authors:  Chunan Bian; Zhongyou Li; Youtao Xu; Jie Wang; Lin Xu; Hongbing Shen
Journal:  World J Surg Oncol       Date:  2015-03-28       Impact factor: 2.754

6.  Expression and significance of transforming growth factor-β receptor type II and DPC4/Smad4 in non-small cell lung cancer.

Authors:  Hong Chen; Jing-Wei Wang; Li-Xin Liu; Ji-Dong Yan; Shu-Hua Ren; Yan Li; Zheng Lu
Journal:  Exp Ther Med       Date:  2014-11-12       Impact factor: 2.447

7.  Astrocyte elevated gene-1(AEG-1) induces epithelial-mesenchymal transition in lung cancer through activating Wnt/β-catenin signaling.

Authors:  Weiling He; Shanyang He; Zuo Wang; Hongwei Shen; Wenfeng Fang; Yang Zhang; Wei Qian; Millicent Lin; Jinglun Yuan; Jinyang Wang; Wenhua Huang; Liantang Wang; Zunfu Ke
Journal:  BMC Cancer       Date:  2015-03-08       Impact factor: 4.430

8.  Overexpression of collagen triple helix repeat containing 1 (CTHRC1) is associated with tumour aggressiveness and poor prognosis in human non-small cell lung cancer.

Authors:  Zunfu Ke; Weiling He; Yuanhui Lai; Xuefeng Guo; Sharon Chen; Shuhua Li; Yuefeng Wang; Liantang Wang
Journal:  Oncotarget       Date:  2014-10-15

9.  Smad4 loss promotes lung cancer formation but increases sensitivity to DNA topoisomerase inhibitors.

Authors:  Sarah M Haeger; Joshua J Thompson; Sean Kalra; Timothy G Cleaver; Daniel Merrick; Xiao-Jing Wang; Stephen P Malkoski
Journal:  Oncogene       Date:  2015-04-20       Impact factor: 9.867

10.  MicroRNA-205 targets SMAD4 in non-small cell lung cancer and promotes lung cancer cell growth in vitro and in vivo.

Authors:  Yuanyuan Zeng; Jianjie Zhu; Dan Shen; Hualong Qin; Zhe Lei; Wei Li; Zeyi Liu; Jian-An Huang
Journal:  Oncotarget       Date:  2017-05-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.